RPEP-09281 · 2024iRGD-camptothecin conjugate showed superior cell penetration, greater colon cancer cell killing at micromolar concentrations, higher tumor accumulation, and enhanced antitumor effects compared to unconjugated camptothecin in both in vitro and in vivo models.
Singh, Tejinder; Kim, Tae Wan; Murthy, Akula S N; Paul, Mohuya; Sepay, Nasim; Jeong Kong, Hye; Sung Ryu, Jae; Rim Koo, Na; Yoon, Sujeong; Song, Keon-Hyoung; Jun Baek, Moo; Jeon, Seob; Im, Jungkyun · Animal Study
RPEP-09282 · 2024Pooled analysis of semaglutide trials showed HR 0.79 (95% CI: 0.69-0.91) for MACE. Predictive modeling forecasts the 9,642-patient SOUL trial will achieve its primary endpoint by 3.78 years, suggesting early termination.
Sinha, Binayak; Ghosal, Samit · Review
RPEP-09283 · 2024Anti-CGRP antibodies increased transition from medication overuse to non-overuse status by 44% overall (RR: 1.44), with the strongest effect in triptan overusers (RR: 1.71) but no significant effect for simple analgesic overusers.
Sirilertmekasakul, Chananchida; Panto, Akkanat; Lekhalawan, Pattanan; Panyarachun, Pariyada; Jindasakchai, Porpim; Rattanawong, Wanakorn · Meta Analysis
RPEP-09284 · 2024GLP-1RAs reduced BMI by 1.02 kg/m² (95% CI: -1.46 to -0.58), FPG by 21.34 mg/dL (95% CI: -29.53 to -13.15), and HbA1c by 0.58% (95% CI: -0.77 to -0.38) more than other second-line treatments over 24 months.
Siriyotha, Sukanya; Anothaisintawee, Thunyarat; Looareesuwan, Panu; Nimitphong, Hataikarn; McKay, Gareth J; Attia, John; Thakkinstian, Ammarin · Cohort
RPEP-09285 · 2024Matrikines derived from ECM protein degradation actively regulate skin cell behavior through specific signaling pathways, with demonstrated therapeutic potential in melanoma, chronic wounds, inflammatory skin diseases, and anti-aging applications.
Sirois, Jonathan P; Heinz, Andrea · Review
RPEP-09286 · 2024Tirzepatide significantly reduced oral contraceptive absorption (AUC, Cmax, and Tmax) while 5 studies of other GLP-1 RAs showed no clinically significant interaction with oral hormonal contraceptives.
Skelley, Jessica W; Swearengin, Katelyn; York, Adriane L; Glover, Lacey H · Review
RPEP-09287 · 2024Kisspeptins regulate both reproduction and metabolism in a sexually dimorphic manner, with disruptions in metabolic conditions leading to simultaneous reproductive dysfunction. Only 15% of clinical studies address kisspeptin's metabolic role.
Sliwowska, Joanna Helena; Woods, Nicola Elizabeth; Alzahrani, Abdullah Rzgallah; Paspali, Elpiniki; Tate, Rothwelle Joseph; Ferro, Valerie Anne · Review
RPEP-09288 · 2024Orforglipron binds GLP-1R with Ki=1 nM, achieves full biological response at low receptor occupancy, has minimal β-arrestin recruitment, and can sustain semaglutide-initiated weight loss when given orally.
Sloop, Kyle W; Cox, Amy L; Wainscott, David B; White, Alex; Droz, Brian A; Stutsman, Cynthia; Showalter, Aaron D; Suter, Todd M; Dunbar, James D; Snider, Brandy M; O'Farrell, Libbey S; Hewitt, Natalie; Ruble, J Craig; Padgett, Leah R; Woerly, Eric M; Peterson, Jeffrey A; Coskun, Tamer; Liu, Zhaomin; Coutant, David E; Ai, Minrong; Emmerson, Paul J; Sangwung, Panjamaporn; Willard, Francis S · In Vitro
RPEP-09289 · 202496.1% approval rate for CGRP mAb applications. ~90% adherence rate. >75% persistence beyond 12 months. €3.2 million first-year expenditure under managed access in Ireland.
Smith, Amelia; Finnigan, Karen; Clarke, Sarah; Barry, Michael; Gorry, Claire · Cohort
RPEP-09290 · 2024dKn2-7-loaded alginate fibers achieved 99% reduction in Candida albicans biofilms on ex vivo porcine skin at 500 µg/mg loading, with no significant tissue damage and preserved hemostatic function.
Snyder, Sabrina S; Rock, Crystal A; Millenbaugh, Nancy J · In Vitro
RPEP-09291 · 2024GET peptide-coated gene gun bullets achieved 13-17-fold higher gene expression than standard bullets and successfully delivered a SARS-CoV-2 DNA vaccine that generated spike-specific T-cell and antibody responses in mice.
So, Roizza Beth; Li, Gang; Brentville, Victoria; Daly, Janet M; Dixon, James E · In Vitro
RPEP-09292 · 2024First reported case of tirzepatide-induced hepatotoxicity in a 37-year-old woman with metabolic syndrome, notable because tirzepatide typically reduces liver fat content.
Sohal, Aalam; Casanova, Luis; Kowdley, Kris V · Case Series
RPEP-09293 · 2024NPY Y1 receptor agonist treatment increased hypothalamic NPY gene expression and improved active swimming behavior in the forced swim test in chronically stressed rats, while depression alone decreased expression of IGF1R, FGF2, POMC, NPY, and GLUT2 genes.
Solak, Hatice; Gormus, Z Isik Solak; Koca, Raviye Ozen; Gunes, Canan Eroglu; Iyisoy, Mehmet Sinan; Kurar, Ercan; Kutlu, Selim · Animal Study
RPEP-09294 · 2024SNAC technology works by three mechanisms: raising local gastric pH to protect semaglutide from acid degradation, shielding the peptide from enzymatic breakdown, and enhancing transcellular absorption across the stomach epithelium — together enabling clinically effective oral delivery of a GLP-1 receptor agonist.
Solis-Herrera, Carolina; Kane, Michael P; Triplitt, Curtis · Review
RPEP-09295 · 2024Semaglutide 2.4 mg weekly significantly reduced left atrial volume progression (-6.13 mL vs placebo, p=0.0013), right ventricular enlargement (RV end-diastolic area -1.99 cm², p=0.016), and improved diastolic filling parameters (E-wave velocity -5.63 cm/s, p=0.0037; E/A ratio -0.14, p=0.0075) over 52 weeks.
Solomon, Scott D; Ostrominski, John W; Wang, Xiaowen; Shah, Sanjiv J; Borlaug, Barry A; Butler, Javed; Davies, Melanie J; Kitzman, Dalane W; Verma, Subodh; Abildstrøm, Steen Z; Nygaard Einfeldt, Mette; Rasmussen, Søren; Abhayaratna, Walter P; Ahmed, Fozia Z; Ben-Gal, Tuvia; Chopra, Vijay; Ito, Hiroshi; Merkely, Bela; Núñez, Julio; Senni, Michele; van der Meer, Peter; Wolf, Dennis; Petrie, Mark C; Kosiborod, Mikhail N · RCT
RPEP-09296 · 2024Serum NPY levels were significantly higher in first-episode schizophrenia patients than controls (p<0.001). In males, NPY positively correlated with PANSS symptom scores at baseline (p<0.01) and changes in NPY tracked with symptom changes during risperidone treatment (p<0.05). No such correlations were found in females. The NPY × sex interaction was highly significant (p<0.001).
Song, Jia-Qi; Xin, Wen; Yu, Jian-Jin; Zhao, Qing; Li, Hong-Na; Chen, Da-Chun · Cohort
RPEP-09297 · 2024National price negotiation led to a significant increase of 212.28 defined daily doses (95% CI: 188.25-236.31, p<0.001) in novel hypoglycaemic drug consumption. Daily costs decreased significantly after policy implementation (p<0.001). Dulaglutide, liraglutide, semaglutide, and dapagliflozin showed significant increases in utilization post-policy (p<0.001).
Song, Jie; Guo, Wei; Jin, Chunlin; Xu, Yuan; Hu, Xiaojing; Zhang, Zheng; Lin, Hai · Cohort
RPEP-09298 · 2024Baseline HbA1c, baseline BMI, and duration of type 2 diabetes were significant predictors of liraglutide response (p<0.05). The combined ROC area under the curve was 0.851 (95% CI: 0.793-0.910), indicating good predictive accuracy.
Song, Jinfang; Li, Na; Zhuang, Yongru; Chen, Ya; Zhang, Chu; Zhu, Jian · Cohort
RPEP-09299 · 2024Three main barriers limit peptide vaccine efficacy: rapid clearance, low immunogenicity, and insufficient uptake by antigen-presenting cells. Synthetic delivery systems targeting lymph node drainage, APC delivery, cross-presentation, and adjuvant incorporation can overcome these barriers and significantly improve anti-tumor immune responses in preclinical models.
Song, Kefan; Pun, Suzie H · Review
RPEP-09300 · 2024Pep4 with levan increased doxorubicin AUC by 2.38-fold (p<0.05) and Cmax by 3.30-fold (p<0.01) compared to control. Pep2 with levan/benzalkonium chloride and Pep3 with levan also significantly enhanced absorption. The peptides work by temporarily opening tight junctions between intestinal epithelial cells.
Song, Keon-Hyoung · Animal Study
RPEP-09302 · 2024Multi-omics profiling identified NPY as significantly downregulated after pulmonary vein ablation. NPY suppression promoted cardiomyocyte apoptosis and activated the Akt pathway in cardiac fibroblasts, increasing fibrosis. NPY intervention alleviated atrial myocyte apoptosis and inhibited Akt activation in fibroblasts. The atrial effective refractory period was shortened after ablation.
Song, Qiyuan; Zhang, Ning; Zhang, Yujiao; Zhang, An; Li, Huilin; Bai, Shuting; Shang, Luxiang; Du, Juanjuan; Hou, Yinglong · Animal Study
RPEP-09303 · 2024APPLRP is a competitive ACE inhibitor with IC50 of 29.93 μM that resists pepsin and pancreatin digestion. In hypertensive zebrafish, it reduced cardiac fibrosis, increased vessel diameter, decreased vessel wall thickness, downregulated ACE expression, and upregulated protective ACE2 expression. In vitro, it blocked Ang II-induced smooth muscle cell proliferation via AT1R/ERK1/2/STAT3 pathway inhibition.
Song, Tianyuan; Zhang, Tiantian; Cai, Qiaolin; Ding, Yin-Yi; Gu, Zhenyu · Animal Study
RPEP-09304 · 2024Complementary and alternative therapies (CAT) show varying levels of evidence for migraine management, while novel peptide-targeting therapies (CGRP antagonists and monoclonal antibodies, PACAP antagonists) represent the most significant pharmacological advance in migraine treatment. The review proposes that CAT may serve as adjunctive therapy alongside these new peptide-based treatments.
Song, Xiaoli; Zhu, Qian; Su, Lanqian; Shi, Lei; Chi, Hao; Yan, Yalan; Luo, Mei; Xu, Xibin; Liu, Baohong; Liu, Zhengyang; Yang, Jin · Review
RPEP-09305 · 2024LC-AMP-F1 inhibited growth of various bacteria including 5 multidrug-resistant clinical strains, effectively inhibited biofilm formation, and disrupted mature biofilms. It showed synergistic or additive effects with conventional antibiotics, minimal hemolytic activity, and low eukaryotic cell toxicity. Mechanism: increased membrane permeability and rapid membrane disruption.
Song, Yuxin; Wang, Junyao; Liu, Xi; Yu, Shengwei; Tang, Xing; Tan, Huaxin · In Vitro
RPEP-09306 · 2024Tβ4 knockout impaired Mauthner cell axon regeneration in zebrafish, while overexpression promoted it. The mechanism requires Tβ4-G-actin binding and promotes actin polymerization (not depolymerization as some models predicted). Axon regeneration length correlated negatively with the straight-tail escape deficit. Tβ4 overexpression restored rapid escape behavior.
Song, Zheng; Han, Along; Hu, Bing · Animal Study
RPEP-09307 · 2024First reported case of euglycemic ketoacidosis caused by semaglutide in a patient without diabetes. The patient presented with metabolic acidosis and ketonemia with normal blood glucose after 7 months of semaglutide for weight loss. Treatment with bicarbonate-containing dextrose infusion resolved the ketoacidosis rapidly.
Sood, Nikhil; Bansal, Ojas; Garg, Rohini; Hoskote, Abhinav · Case Series
RPEP-09308 · 2024Among 9,441 ICSRs, 12.8% involved cardiovascular adverse events (1,205 reports, 1,599 CV ADRs). 67.5% of CV ADRs were serious. Disproportionate reporting: erenumab — hypertension (ROR 1.45); galcanezumab — atrial fibrillation (ROR 2.36), myocardial infarction (ROR 2.21); fremanezumab — deep vein thrombosis (ROR 3.86), pallor (ROR 5.00), palpitations (ROR 1.48). Several findings not in official drug labels.
Sorbara, Emanuela Elisa; Barbieri, Maria Antonietta; Russo, Giulia; Cicala, Giuseppe; Spina, Edoardo · Cohort
RPEP-09309 · 2024Cathelicidin is rapidly produced by uroepithelial cells upon pathogen contact, making it a potential early UTI biomarker. Post-UTI cathelicidin levels lower than healthy controls suggest a risk factor for recurrence. Cathelicidin also shows promise as a biomarker for severe vesicoureteral reflux and renal scarring. Multiple therapeutic agents that upregulate cathelicidin expression are under investigation.
Sorić Hosman, Iva; Cvitković Roić, Andrea; Vuković Brinar, Ivana; Gulin, Tonko; Ćorić, Marijana; Rogić, Dunja; Lončar Vrančić, Ana; Lamot, Lovro · Review
RPEP-09310 · 2024Bioactive dipeptides YA, VL, and IY from poultry hydrolysates resisted simulated gastrointestinal digestion. However, Caco-2 cell monolayer absorption tests showed peptide concentrations decreased on the apical side but were not detected basolaterally — indicating cellular uptake/metabolism rather than transcellular transport. The peptides downregulated peptide transporter expression, CDX2 transcription factor, and tight junction protein TJP1.
Sorokina, Liudmila; Solberg, Nina Therese; Koga, Shiori; Rønning, Sissel Beate; Afseth, Nils Kristian; Wilson, Steven Ray; Rieder, Anne; Wubshet, Sileshi Gizachew · In Vitro
RPEP-09311 · 2024A lead peptide identified from phage display against primary CF bronchial epithelial cells enhanced mRNA lipid nanoparticle delivery by 7.8-fold in vitro (primary human CF bronchial epithelia) and 3.4-fold in vivo (mouse lungs). The peptide facilitated specific uptake into lung epithelial cells relative to other cell types.
Soto, Melissa R; Lewis, Mae M; Leal, Jasmim; Pan, Yuting; Mohanty, Rashmi P; Veyssi, Arian; Maier, Esther Y; Heiser, Brittany J; Ghosh, Debadyuti · In Vitro
RPEP-09312 · 20248 of 11 clinicaltrials.gov-specified efficacy outcomes were unpublished, including FSDS-DAO total score, FSFI total score, FSFI arousal domain, and FSEP-R items. Analyzed unpublished outcomes showed effect sizes from nil to small. Published categorical response outcomes lacked validity evidence. Nearly all outcomes suggesting modest benefits were likely post-hoc.
Spielmans, Glen I; Ellefson, Elaine M · Review
RPEP-09313 · 2024161Tb-DOTATATE and 161Tb-DOTA-LM3 delivered 3.6× and 3.8× higher nuclear absorbed doses than 177Lu-labeled counterparts. The enhanced dose was primarily from internal conversion electrons, not Auger electrons. 161Tb-DOTA-LM3 showed a superior linear-quadratic dose response (suggesting additional membrane damage) compared to the linear-only response of 161Tb-DOTATATE.
Spoormans, Kaat; Struelens, Lara; Vermeulen, Koen; De Saint-Hubert, Marijke; Koole, Michel; Crabbé, Melissa · In Vitro
RPEP-09314 · 2024GLP-1 RAs significantly reduce cardiovascular mortality, all-cause mortality, nonfatal MI, and nonfatal stroke in T2DM patients with existing cardiovascular risk factors. Limited data suggest possible protective effects against arrhythmias. Effects on heart failure hospitalization are minor. Benefits in patients without cardiovascular risk factors are uncertain.
Sreenivasan, Chithra; Parikh, Aneri; Francis, Aida J; Kanthajan, Tatchaya; Pandey, Manorama; AlQassab, Osamah; Nath, Tuheen Sankar · Review
RPEP-09316 · 2024BMI decreased significantly from 34.0 to 31.0 (p<0.0001) with median weight loss of 8.15 kg (p<0.0001). CRP and ALT levels did not change significantly, suggesting no worsening of IBD inflammation. Total cholesterol and HbA1c showed trends toward improvement. Side effects: nausea (31%), constipation (25%).
St-Pierre, Joëlle; Klein, Jeremy; Choi, Natalie K; Fear, Evan; Pannain, Silvana; Rubin, David T · Cohort
RPEP-09317 · 2024Semaglutide decelerated tumor appearance and growth in 4T1 breast cancer mice. No direct cytotoxic effect in vitro and no angiogenic effect. NK cell depletion did not affect tumor growth in treated mice. Semaglutide increased CD11c+ dendritic cell accumulation and maturation, decreased FoxP3+ regulatory T cells (in spleen and tumor), increased tumor-infiltrating T cells with anti-tumor phenotype, and enhanced CD8+ T cell cytotoxic capacity.
Stanisavljevic, Isidora; Pavlovic, Sladjana; Simovic Markovic, Bojana; Jurisevic, Milena; Krajnovic, Tamara; Mijatovic, Sanja; Spasojevic, Marija; Mitrovic, Slobodanka; Corovic, Irfan; Jovanovic, Ivan · Animal Study
RPEP-09318 · 2024Over 25% of total weight lost from both bariatric surgery and GLP-1 pharmacotherapy comes from fat-free mass. The myostatin-activin-follistatin system is crucial for lean mass preservation during negative energy balance. Bimagrumab, trevogrumab, and garetosmab inhibit activin/myostatin signaling and show promise in preventing muscle loss while promoting fat loss, either alone or combined with incretin receptor agonists.
Stefanakis, Konstantinos; Kokkorakis, Michail; Mantzoros, Christos S · Review
RPEP-09319 · 2024GLP-1/GIP RAs vs placebo in non-diabetic overweight/obese adults: MACE reduced (OR 0.79, 95% CI 0.71-0.89), all-cause mortality reduced (OR 0.80, 95% CI 0.70-0.92), MI reduced (OR 0.72, 95% CI 0.61-0.86), nonfatal MI reduced (OR 0.72, 95% CI 0.61-0.85). Cardiovascular mortality trend (OR 0.84, 95% CI 0.71-1.01, p=0.06). No significant stroke reduction. No heterogeneity across studies (I²=0 for all outcomes).
Stefanou, Maria-Ioanna; Palaiodimou, Lina; Theodorou, Aikaterini; Safouris, Apostolos; Fischer, Urs; Kelly, Peter J; Dawson, Jesse; Katan, Mira; Katsanos, Aristeidis H; Lambadiari, Vaia; Giannopoulos, Sotirios; Alexandrov, Andrei V; Siasos, Gerasimos; Tsivgoulis, Georgios · Meta Analysis
RPEP-09320 · 2024One of four patients with mCRPC had three bone metastases that were positive for both PSMA (confirming prostate cancer) and gallium-68-DOTA-exendin-4 (confirming GLP-1R expression). This is the first in vivo demonstration of GLP-1R expression in metastatic prostate cancer. The patient had six PSMA-avid lesions, three of which were also exendin-avid.
Stein, Mark S; Kalff, Victor; Williams, Scott G; Murphy, Declan G; Colman, Peter G; Hofman, Michael S · Cohort
RPEP-09321 · 2024A 30% decline in spleen volume at 12 months post-177Lu-DOTATATE treatment predicted leukopenia at 24 months with AUC 0.91, sensitivity 93%, and specificity 90%. White blood cell counts and relative spleen volume reduction were also independent predictors, but spleen volume reduction was far superior. Automated splenic volume assessment outperformed all conventional laboratory parameters.
Steinhelfer, Lisa; Jungmann, Friederike; Endrös, Lukas; Wenzel, Patrick; Haller, Bernhard; Nickel, Manuel; Haneder, Eva; Geisler, Fabian; Götze, Katharina; von Werder, Alexander; Eiber, Matthias; Makowski, Markus R; Braren, Rickmer; Lohöfer, Fabian · Cohort
RPEP-09322 · 2024At 2 years: bariatric surgery achieved 26.4% ± 8.83% total weight loss vs 5.2% ± 7.87% with semaglutide (p<0.001). Mean HbA1c: 42.3 ± 11.18 after surgery vs 50.7 ± 12.48 after semaglutide (p<0.001). Complete diabetes remission: 63.0% with surgery vs 13.9% with semaglutide (p<0.001).
Stenberg, Erik; Cao, Yang; Ottosson, Johan; Hedberg, Suzanne; Näslund, Erik · Cohort
RPEP-09323 · 2024Difficulties in emotion regulation significantly predicted psychopathology (B=0.032, p<0.01). This relationship was significantly moderated by NPY levels (B=-0.001, p<0.05) — higher NPY weakened the emotion-regulation-to-psychopathology link. The overall model was significant (R²=0.26, F(5,48)=3.46, p<0.01).
Stevens, Sarah K; Boley, Randy; Pollack, Mark; Hobfoll, Stevan; Shankman, Stewart; Pinkerton, Linzy; Valdespino-Hayden, Zerbrina; Glover, Angela C; Kaufman, Michelle; Dowd, Sheila; Zalta, Alyson K · Cohort
RPEP-09324 · 2024All 6 biomarkers — BNP, troponin I, cystatin-C, CRP, D-dimer, and midregional proadrenomedullin — were significantly associated with cardiovascular death (n=1,903) both during the randomized trial period and for 10 additional years after trial completion (each p<0.001). Associations were sustained for at least 15 years total.
Stewart, Ralph A H; Robledo, Kristy P; Tonkin, Andrew M; Keech, Anthony; Kritharides, Leonard; Marschner, Ian; Janus, Edward; Thompson, Peter L; Watts, Gerald F; Zeller, Tanja; White, Harvey D; Simes, John · Cohort
RPEP-09325 · 2024Liraglutide dose-dependently inhibited LPS-induced apoptosis and inflammation in cardiac cells via GLP-1R-mediated cAMP production. AC inhibition completely abolished liraglutide's anti-inflammatory effects. Roflumilast (PDE4 inhibitor) enhanced cAMP production and amplified liraglutide's protection. Both PKA and Epac pathways are required — inhibiting either alone only partially blocked effects, but inhibiting both fully prevented liraglutide's anti-inflammatory action.
Stoicovy, Renee A; Cora, Natalie; Perez, Arianna; Nagliya, Deepika; Del Calvo, Giselle; Lopez, Teresa Baggio; Weinstein, Emma C; Borges, Jordana I; Maning, Jennifer; Lymperopoulos, Anastasios · In Vitro
RPEP-09326 · 2024Semaglutide improved left ventricular ejection fraction at rest and during rapid pacing (both p<0.03), increased perfusion to the most ischemic myocardium at rest and during pacing (both p<0.03), reduced perivascular and interstitial fibrosis (both p<0.03), and decreased apoptosis (p=0.008). Mechanism: increased AMPK activation (p=0.005) with downstream eNOS upregulation (p=0.014).
Stone, Christopher R; Harris, Dwight D; Broadwin, Mark; Kanuparthy, Meghamsh; Nho, Ju-Woo; Yalamanchili, Keertana; Hamze, Jad; Abid, M Ruhul; Sellke, Frank W · Animal Study
RPEP-09327 · 2024Tirzepatide 2.5 mg weekly decreased postprandial glucose peaks, increased postprandial glucose nadirs (preventing dangerous hypoglycemia), improved time in range on CGM, and resolved postprandial bloating and diarrhea from dumping syndrome. First reported use of a dual-incretin agonist for either dumping syndrome or postbariatric hypoglycemia.
Stortz, Ethan; Lawler, Helen · Case Series
RPEP-09328 · 2024Oral semaglutide significantly reduced liver stiffness (8.07 ± 2.90 → 6.51 ± 3.09 kPa, p<0.001) measured by VCTE at 6 months. Both groups showed reduced BMI, waist circumference, and waist-to-hip ratio. Semaglutide showed notable HbA1c decrease (p-value referenced). Both were add-on to metformin.
Stratina, Ermina; Stanciu, Carol; Nastasa, Robert; Zenovia, Sebastian; Stafie, Remus; Rotaru, Adrian; Cuciureanu, Tudor; Muzica, Cristina; Sfarti, Catalin; Girleanu, Irina; Minea, Horia; Petrea, Oana; Huiban, Laura; Chiriac, Stefan; Singeap, Ana-Maria; Vlad, Oana; Cojocariu, Camelia; Trifan, Anca · Cohort
RPEP-09329 · 2024Retinoic acid stimulated human neutrophils to produce LL-37 antimicrobial peptide, reactive oxygen species, and extracellular traps, enhancing MRSA killing in vitro. RA directly inhibited GAS growth and, in a murine skin infection model, topical RA reduced both skin lesion size and bacterial burden.
Stream, Alexandra; Corriden, Ross; Döhrmann, Simon; Gallo, Richard L; Nizet, Victor; Anderson, Ericka L · In Vitro
RPEP-09330 · 2024After four PRRT cycles in 40 NET patients, CgA, VEGF-R1, and VEGF-R2 decreased significantly while VEGF-R3 increased. VEGF levels were unchanged. VEGF-R1 had the best discriminatory value for treatment response (AUC 0.7).
Strzelczyk, Janusz; Wójcik-Giertuga, Monika; Makulik, Karolina; Rosiek, Violetta; Kamiński, Grzegorz; Kajdaniuk, Dariusz; Kos-Kudła, Beata · Cohort
RPEP-09331 · 2024Ghrelin, anamorelin, HM01, and HM03 behaved as potent full GHSR agonists in both assays. LEAP2(1-14) was identified as a GHSR inverse agonist in DMR but not calcium assays. PF-05190457, HM04, and H1498 acted as inverse agonists in DMR but only antagonists in calcium mobilization, demonstrating DMR's superior ability to discriminate receptor pharmacology.
Sturaro, Chiara; Ruzza, Chiara; Ferrari, Federica; Pola, Pietro; Argentieri, Michela; Frezza, Alessia; Marzola, Erika; Bettegazzi, Barbara; Cattaneo, Stefano; Pietra, Claudio; Malfacini, Davide; Calò, Girolamo · In Vitro
RPEP-09332 · 2024Pasireotide-induced hyperglycemia is pathophysiologically distinct — caused by decreased GIP and GLP-1 secretion, not insulin resistance. Incretin-based therapeutics (DPP-4 inhibitors and GLP-1 RAs) are recommended as alternatives to metformin monotherapy because they target the specific mechanism. Patient risk stratification and monitoring protocols are proposed.
Störmann, Sylvère; Meyhöfer, Sebastian M; Groener, Jan B; Faust, Johanna; Schilbach, Katharina; Seufert, Jochen; Vergès, Bruno · Review